Format

Send to

Choose Destination
Clin Infect Dis. 2017 Feb 1;64(3):355-360. doi: 10.1093/cid/ciw788. Epub 2016 Dec 7.

MASTERMIND: Bringing Microbial Diagnostics to the Clinic.

Author information

1
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, and Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota; patel.robin@mayo.edu.
2
Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
3
David Geffen School of Medicine and Fielding School of Public Health, University of California, Los Angeles; and.
4
Center for Biostatistics in AIDS Research and the Department of Biostatistics, Harvard University, Boston, Massachusetts.

Abstract

New diagnostics are urgently needed to address emerging antimicrobial resistance. The Antibacterial Resistance Leadership Group proposes a strategy called MASTERMIND (Master Protocol for Evaluating Multiple Infection Diagnostics) for advancement of infectious diseases diagnostics. The goal of this strategy is to generate the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by promoting research that might not have otherwise been feasible with conventional trial designs. MASTERMIND uses a single subject's sample(s) to evaluate multiple diagnostic tests at the same time, providing efficiencies of specimen collection and characterization. MASTERMIND also offers central trial organization, standardization of methods and definitions, and common comparators.

KEYWORDS:

communicable diseases; molecular diagnostic techniques; reference standards.

PMID:
27927867
PMCID:
PMC5894935
DOI:
10.1093/cid/ciw788
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center